When Chemotherapy Can Be Avoided: Genomic Risk-Stratification in Early Breast Cancer

A whole-abdomen ultrasound, not just the upper abdomen, checks for liver metastasis and also covers the ovaries and uterus. A chest X-ray checks for lung metastasis. For bone, a skeletal survey, plain X-rays covering the spine, skull and limbs, substitutes for a bone scan where nuclear medicine isn't available. This combination is less accurate than PET CT but is a reasonable, optimal fallback when resources are limited.

For a young patient with early, well-localised disease, breast conservation surgery is advisable over mastectomy: a wide excision with lymph node dissection or sentinel biopsy, followed by pathology review. If the oestrogen receptor is positive on the final specimen, tamoxifen is started after surgery, and chemotherapy is added if indicated by the pathology. Starting tamoxifen before surgery is not advisable.

Neoadjuvant chemotherapy should be started before referral in two situations: triple-negative breast cancer, and locally advanced disease, meaning a tumour over 5 cm, ulceration, peau d'orange skin change, satellite nodules, or bulky or supraclavicular nodes. In locally advanced disease, surgery follows after around four to four and a half months of chemotherapy. In genuinely advanced or metastatic disease, treatment is systemic only, chemotherapy or hormone therapy, with no surgery. For anything in between, it is always better to discuss the specific case jointly before deciding independently whether and when to start treatment.

No, a BRCA1 and BRCA2 test should be done first. Indications for testing are all triple-negative breast cancer, a strong first-degree family history (a sister, mother, or maternal or paternal aunt with breast cancer), and any history of male breast cancer in the family, which alone is enough to warrant testing. If the BRCA test comes back positive, mastectomy of the affected breast should be combined with prophylactic mastectomy of the opposite side. If BRCA testing isn't available locally, it can be arranged through Dr. Jain's centre.

There is no single definitive treatment; breast cancer, like all solid tumours, requires multimodal treatment. Chemotherapy alone, radiotherapy alone, or hormone therapy alone cannot cure it. Surgery has to be part of the treatment plan for a cure, combined with hormone therapy, chemotherapy or radiation as indicated, though surgery alone is occasionally sufficient in very select cases.

Yes, in a meaningful subset. Genomic risk-stratification tests such as Oncotype DX, MammaPrint, EndoPredict or Canassist identify low-risk, hormone receptor-positive, HER2-negative patients for whom hormone therapy alone is sufficient, sparing roughly 50-60% of this group from chemotherapy in Dr. Jain's practice.

Aromatase inhibitors, one of the two main hormone therapy options, only work once a patient is postmenopausal. A premenopausal patient who needs this class of drug requires ovarian suppression or removal first, since the ovaries are the primary source of the oestrogen that drives breast cancer growth.